Search Results

You are looking at 101 - 110 of 161 items for :

  • "systemic treatment" x
Clear All
Full access

David S. Ettinger, Douglas E. Wood, Wallace Akerley, Lyudmila A. Bazhenova, Hossein Borghaei, David Ross Camidge, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D'Amico, Thomas Dilling, Michael Dobelbower, Ramaswamy Govindan, Mark Hennon, Leora Horn, Thierry M. Jahan, Ritsuko Komaki, Rudy P. Lackner, Michael Lanuti, Rogerio Lilenbaum, Jules Lin, Billy W. Loo Jr, Renato Martins, Gregory A. Otterson, Jyoti D. Patel, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, Neelesh Sharma, Scott J. Swanson, James Stevenson, Kurt Tauer, Stephen C. Yang, Kristina Gregory and Miranda Hughes

. Systemic therapy options for malignant pleural mesothelioma beyond first-line therapy: a systematic review . Expert Rev Respir Med 2015 ; 9 : 533 – 549 . 59. Christoph DC Eberhardt WE . Systemic treatment of malignant pleural mesothelioma

Full access

Margaret A. Tempero, Mokenge P. Malafa, Stephen W. Behrman, Al B. Benson III, Ephraim S. Casper, E. Gabriela Chiorean, Vincent Chung, Steven J. Cohen, Brian Czito, Anitra Engebretson, Mary Feng, William G. Hawkins, Joseph Herman, John P. Hoffman, Andrew Ko, Srinadh Komanduri, Albert Koong, Andrew M. Lowy, Wen Wee Ma, Nipun B. Merchant, Sean J. Mulvihill, Peter Muscarella II, Eric K. Nakakura, Jorge Obando, Martha B. Pitman, Sushanth Reddy, Aaron R. Sasson, Sarah P. Thayer, Colin D. Weekes, Robert A. Wolff, Brian M. Wolpin, Jennifer L. Burns and Deborah A. Freedman-Cass

following systemic treatment of initially locally unresectable disease . Ann Surg Oncol 2012 ; 19 : 1663 – 1669 . 45. Faris JE Blaszkowsky LS McDermott S . FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital

Full access

Cindy Railton, Sasha Lupichuk, Jennifer McCormick, Lihong Zhong, Jenny Jaeeun Ko, Barbara Walley, Anil A. Joy and Janine Giese-Davis

Trialists' Collaborative Group . Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women . Lancet 1992 ; 339 : 1 – 15 . 25

Full access

Neil K. Taunk, Daniel E. Spratt, Mark Bilsky and Yoshiya Yamada

prognosis in patients with RCC. 3 , 4 Even with these advances in systemic treatment, radiation therapy (RT) continues to play a significant role in managing patients with metastatic disease to the brain and spine. RT is used for palliation of painful bone

Full access

Zeynep Eroglu, Odicie Fielder and George Somlo

breast cancer patients receiving first-line systemic treatment . Breast Cancer Res 2011 ; 13 : R67 . 36. Munzone E Botteri E Sandri MT . Prognostic value of circulating tumor cells according to immunohistochemically defined molecular

Full access

Paolo Marchetti, Raymond Voltz, Carmen Rubio, Didier Mayeur and Andreas Kopf

have no curative treatment options, and that it should be integrated soon after completing cancer staging and starting disease-specific systemic treatment and delivered at the same location as anticancer therapy. Examples of timing for integration of

Full access

Rupali Roy and Leo I. Gordon

developed by the international follicular lymphoma prognostic factor project . J Clin Oncol 2009 ; 27 : 4555 – 4562 . 11 Ardeshna KM Smith P Norton A . Long-term effect of a watch and wait policy versus immediate systemic treatment for

Full access

Manish A. Shah and David P. Kelsen

; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research . J Clin Oncol 2007 ; 25 : 3217 – 3223 . 57. Van Cutsem E

Full access

Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Lynette Cederquist, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Paul F. Engstrom, Ignacio Garrido-Laguna, Jean L. Grem, Axel Grothey, Howard S. Hochster, Sarah Hoffe, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Eric D. Miller, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Evan Wuthrick, Kristina M. Gregory and Deborah A. Freedman-Cass

unresectable, advanced, or metastatic CRC (mCRC) were managed with a continuum of care that included 20 first-line systemic treatment options, 33 second-line options, and 13 options for subsequent therapies in up to 7 lines of treatment. 28 , 29 A growing list

Full access

Brandon R. Mason, James A. Eastham, Brian J. Davis, Lance A. Mynderse, Thomas J. Pugh, Richard J. Lee and Joseph E. Ippolito

, distant metastatic disease, and a combination of both is critical, because this will affect whether the patient will receive local salvage and or systemic treatment. 52 Therefore, imaging modalities that have the ability to detect recurrent local and